Dr. David Wofsy, MD

NPI: 1619932886
Total Payments
$150,080
2023 Payments
$26,309
Companies
16
Transactions
69

Payment Breakdown by Category

Consulting$123,907 (82.6%)
Research$19,659 (13.1%)
Travel$5,710 (3.8%)
Food & Beverage$804.26 (0.5%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $123,907 47 82.6%
Unspecified $19,659 3 13.1%
Travel and Lodging $5,710 9 3.8%
Food and Beverage $804.26 10 0.5%

Payments by Type

General
$130,421
66 transactions
Research
$19,659
3 transactions

Top Paying Companies

Company Total Records Latest Year
Celgene Corporation $50,034 9 $0 (2019)
Amgen Inc. $24,280 14 $0 (2023)
GlaxoSmithKline, LLC. $21,327 10 $0 (2022)
Novartis Pharma AG $14,709 2 $0 (2023)
SANOFI-AVENTIS U.S. LLC $10,550 8 $0 (2022)
Genentech, Inc. $6,172 4 $0 (2019)
Eli Lilly and Company $6,019 6 $0 (2022)
NOVARTIS PHARMACEUTICALS CORPORATION $3,599 1 $0 (2023)
Janssen Research & Development, LLC $3,125 2 $0 (2020)
UCB GmBH $2,456 2 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2023 $26,309 7 Novartis Pharma AG ($14,709)
2022 $13,718 10 Amgen Inc. ($11,600)
2021 $8,610 5 Amgen Inc. ($5,800)
2020 $7,440 5 Janssen Research & Development, LLC ($3,100)
2019 $41,307 17 Celgene Corporation ($25,000)
2018 $13,925 5 Celgene Corporation ($6,250)
2017 $38,772 20 Celgene Corporation ($18,784)

All Payment Transactions

69 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
12/12/2023 Novartis Pharma AG COSENTYX (Biological) Cash or cash equivalent $14,600.00 Research
Study: Rheumatology Pipeline Studies • Category: IMMUNOLOGY
12/12/2023 Novartis Pharma AG COSENTYX (Biological) Cash or cash equivalent $109.23 Research
Study: Rheumatology Pipeline Studies • Category: IMMUNOLOGY
09/22/2023 NOVARTIS PHARMACEUTICALS CORPORATION Travel and Lodging In-kind items and services $3,599.31 General
05/02/2023 IDORSIA PHARMACEUTICALS US INC CENERIMOD Consulting Fee Cash or cash equivalent $1,620.00 General
03/27/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
03/08/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $2,900.00 General
01/17/2023 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
12/21/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,160.00 General
11/11/2022 Eli Lilly and Company Food and Beverage In-kind items and services $45.94 General
09/22/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
08/25/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
05/26/2022 GlaxoSmithKline, LLC. BENLYSTA (Biological) Consulting Fee Cash or cash equivalent $576.76 General
Category: IMMUNOLOGY
05/24/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
05/20/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
05/12/2022 SANOFI-AVENTIS U.S. LLC Consulting Fee Cash or cash equivalent $1,495.00 General
02/24/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
01/28/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $1,740.00 General
11/15/2021 Amgen Inc. Consulting Fee Cash or cash equivalent $2,320.00 General
07/14/2021 Amgen Inc. Consulting Fee Cash or cash equivalent $2,320.00 General
07/08/2021 Janssen Global Services, LLC STELARA (Biological) Consulting Fee Cash or cash equivalent $810.00 General
Category: Immunology
03/30/2021 GlaxoSmithKline, LLC. BENLYSTA (Biological) Consulting Fee Cash or cash equivalent $2,000.00 General
Category: IMMUNOLOGY
03/22/2021 Amgen Inc. Consulting Fee Cash or cash equivalent $1,160.00 General
11/12/2020 Janssen Global Services, LLC STELARA (Biological) Consulting Fee Cash or cash equivalent $540.00 General
Category: Immunology
10/13/2020 GlaxoSmithKline, LLC. Consulting Fee Cash or cash equivalent $1,500.00 General
06/25/2020 Janssen Research & Development, LLC STELARA (Biological) Consulting Fee Cash or cash equivalent $3,100.00 General
Category: Immunology

Research Studies & Clinical Trials

Study Name Company Amount Records
Rheumatology Pipeline Studies Novartis Pharma AG $14,709 2

About Dr. David Wofsy, MD

Dr. David Wofsy, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619932886.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Wofsy, MD has received a total of $150,080 in payments from pharmaceutical and medical device companies, with $26,309 received in 2023. These payments were reported across 69 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($123,907).

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Rheumatology
  • Location San Francisco, CA
  • Active Since 04/19/2006
  • Last Updated 09/11/2025
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1619932886

Products in Payments

  • COSENTYX (Biological) $14,709
  • NO PRODUCT DISCUSSED (Drug) $9,055
  • BENLYSTA (Biological) $8,327
  • GAZYVA (Biological) $6,172
  • STELARA (Biological) $4,450
  • NINLARO (Drug) $1,922
  • CENERIMOD $1,620
  • Enbrel (Biological) $500.00
  • Tremfya (Drug) $25.36

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in San Francisco